Board Certified Radiation Oncologist @StarlingOnc| formerly trained at @DukeRadOnc | @Duke undergrad alum
Los Angeles, CA
Joined November 2009
- Tweets2.6K
- Following740
- Followers788
- Likes7.6K
Pinned Tweet
🧵 Tweetorial:
1/
MRI is now central to prostate cancer workup — but does what we see on MRI predict outcomes?
In a national cohort of 2,275 veterans, we found that MRI-detected EPE is common & highly prognostic.
MRI-detected extraprostatic extension, including major capsule abutment, is common in localized #ProstateCancer (PC) and independently prognostic. MRI findings should be considered in the next iteration of PC staging.
acsjournals.onlinelibrary.wi…
@OncoAlert #RadOnc #PCSM
Abhishek ("Shake") Kumar, MD MAS retweeted
🚨#ESMO26 Localised stage II-IIIB gastroesophageal cancer; n=1024 patient trial from 🇨🇳 indicates de-escalated 4 months of adjuvant XELOX is non-inferior to 6 months XELOX . V important as tolerance of these regimens is a big issue! #gcsm @marklewismd
Abhishek ("Shake") Kumar, MD MAS retweeted
🚨🔔🔔Very happy to announce that we have randomised the first patient into @TOGAANZ and @TROGfightcancer phase III, PRIME-lung trial! First site open @PeterMacCC
➡️ this newly open 420 patient phase III trial investigates whether the addition of high dose radiation to the lung primary in patients with non-small cell lung cancer can be life-prolonging (primary endpoint OS)
➡️ Thank you all investigators and patients, this is just the beginning! #lungcancer #lcsm
Abhishek ("Shake") Kumar, MD MAS retweeted
Check out what makes the Duke #RadOnc residency program exceptional on our website (and make sure you scroll down to watch our residency overview video!): radonc.duke.edu/education/ra… #MedStudents #Match2027 #MatchDay @ARRO_org
ALT Infographic with blue and white checkerboard squares, showing a graduation cap with text ">70% of graduates in academic medicine"; a map of the United States with text "coast-to-coast early job placement in a wide range of careers"; a star trophy with text "16 FASTRO faculty members"; a brain outline with text "multiple tracks including RORS for a tailored residency experience"; a microscope with text "unique concentrations mini-fellowships to develop mastery of desired skills"; and a stethoscope with text "highly rated VA rotations with graduated autonomy each clinical year."
Abhishek ("Shake") Kumar, MD MAS retweeted
1/6:
I am excited to share our multi-institutional F-SHARP phase I/II trial, now published in @JCO_ASCO!
doi.org/10.1200/JCO-25-02730
There are limited prospective data defining the optimal management of intraprostatic radiorecurrence (IPR) after definitive RT for prostate cancer.
We asked:
1. Is dose-escalated focal salvage high dose rate brachytherapy safe and effective for IPR?
2. Can Decipher (@Veracyte) identify patients with higher risk of recurrence with salvage ReRT that may benefit from therapeutic intensification?
🧵👇
Abhishek ("Shake") Kumar, MD MAS retweeted
🚨 #ARCHER @NRGonc GU 15 AMENDMENT
✅ Neoadjuvant and Adjuvant Therapy Explicitly Allowed
✅ TURBT→enrollment: 240 days with ≥3 NAT cycles
✅ Week-16 biopsy only if indicated
✅ Less frequent surveillance after year 2
✅ Local chemo/telehealth
✅ Updated adaptive RT/QA + utDNA collection
Same trial: 20 vs 5 fractions. #BladderCancer
#ASTRO26 @ASTRO_org
@UroCancer @drjefstathiou @SeanSachdevMD @ndesai2005 @l_ballas @IyerGopa @Dr_Aggen @shilpaonc @DrMBWesterman @Katie_Spina @MiyamotoDavid @AdityaBagrodia @jonathan_leeman @KashaniRojano @KateMRGuidance @abhiAsolanki
Abhishek ("Shake") Kumar, MD MAS retweeted
New in #practicalRO: Evaluation of Cases with Over 10 Years of Follow-up After Stereotactic Body Radiotherapy for Stage I Lung Cancer. This article was presented during #ASTRO2026 in Poster Q&A Session 07. bit.ly/4hAtMbt
Abhishek ("Shake") Kumar, MD MAS retweeted
In other words, post-treatment PSA does not (completely) overrule pre-treatment risk.
Same for undetectable PSA after RP. And probably true for pCR/MRD/RCB after neoadjuvant treatment.
Abhishek ("Shake") Kumar, MD MAS retweeted
An important topic that is frequently discussed during many GI tumor boards.
How do we conceptualize/treat oligoprogressive and OMD?
Thank you @KrishanJethwa for mentoring and working on this with me!
apm.amegroups.org/article/vi…
Abhishek ("Shake") Kumar, MD MAS retweeted
New #VirtualTumorBoard presents a patient with recurrent #ProstateCancer after radical prostatectomy, covering biochemical recurrence to metastatic disease.
🔗: acsjournals.onlinelibrary.wi…
@OncoAlert @AmarUKishan @omgitsyuliaz @KekoaMDPhD @MSteinbergMD @CalaisJeremie #PCAM
Abhishek ("Shake") Kumar, MD MAS retweeted
Good morning. Here are QBR rankings 4 games in….
1. Brock Purdy: 89.6
2. Dak Prescott: 83.3
3. Lamar Jackson: 81.3
4. Bryce Young: 74.6
5. Trevor Lawrence: 73.0
Abhishek ("Shake") Kumar, MD MAS retweeted
Placebo Controlled Randomized Trial: Memantine given w/Brain RT Improved Cognitive Outcomes & QOL 1/3 sciencedirect.com/science/ar…
Abhishek ("Shake") Kumar, MD MAS retweeted
You are the hope. Never doubt that.
There is always a patient behind each of those studies. A patient like me.
—Felix Feng ❤️
Abhishek ("Shake") Kumar, MD MAS retweeted
Amazing work, congratulations!
Make that THREE papers this week! 🚨
RAPTOR is out: 3,120 men & 11 RCTs. After RT alone, being BCR-free at 5y marked a functional-cure benchmark (8y DM 6.6%; 10y PCSM 2.5%). W/ ADT, late metastatic risk persisted.
doi.org/10.1016/j.euo.2026.0… @AmarUKishan @DrSpratticus @alison_tree
Abhishek ("Shake") Kumar, MD MAS retweeted
💡SWOG/NRG S1914
🔹 417 pts T1-T3N0 NSCLC ≤7 cm, inoperable/declined surgery
🔹 OS HR 1.04 (0.69-1.58)
🔹 2y OS 82% in both arms
🔹 Grade ≥3 AE: 12% atezo (2 Gr5 resp) vs 3% SBRT
➡️ SBRT alone remains SOC. 🫁
Abhishek ("Shake") Kumar, MD MAS retweeted
Make that THREE papers this week! 🚨
RAPTOR is out: 3,120 men & 11 RCTs. After RT alone, being BCR-free at 5y marked a functional-cure benchmark (8y DM 6.6%; 10y PCSM 2.5%). W/ ADT, late metastatic risk persisted.
doi.org/10.1016/j.euo.2026.0… @AmarUKishan @DrSpratticus @alison_tree
Two papers in a week! 🚨
Now out in @IJROBP: after testosterone recovery following RT+ADT, faster PSA kinetics were associated w/ progression but the relationship with metastatic risk was inconsistent. redjournal.org/article/S0360…
Just days after our NADIR validation in ARCHES! 🔬
Abhishek ("Shake") Kumar, MD MAS retweeted
The future looks bright with these three outstanding #WomenWhoCurie leading ASTRO.
Dr. Neha Vapiwala is our new Board Chair, Dr. Catheryn Yashar is now ASTRO President and Dr. Beth Erickson is our President-Elect. #ASTRO26
@ASTRO_Chair @NehaVapiwala @catherynyashar @BethEri81895034 @S_W_R_O @ARRO_org @RadOncPDs
Abhishek ("Shake") Kumar, MD MAS retweeted
I discuss this with all my UIR patients and it certainly has been a factor in some of them choosing surgery. It is part of the treatment package.
Fortunately we have great investigators evaluating who may be a candidate for deescalation.
Yes you raise an important point @DongNguyeb - short term ADT is often part of the package deal of radiotherapy for unfavorable intermediate risk prostate cancer. And of course causes sexual problems.
Good news is there are emerging biomarkers (ARTERA and now Decipher) that are helping us select which pts to omit ADT and do radiation as a Monotherapy. Approximately 2/3 can omit!
I’m an optimist. There are exciting, better days ahead for our patients with prostate cancer for each treatment modality.
My main point I will continue to share is patients should understand ALL standard options— and consult with both urology and radiation oncology—and should decide what’s best for them. I think we both agree on this 🤝🏾
Fine.
And RadioOnco should also note this: the advantage of SBRT over RP in sexual function was only assessed under the conditions of the PACE-A study, where ADT was not permitted.
This does not reflect current practice, because after SBRT, omitting STADT in unfavorable intermediate-risk patients is still not permitted , yet this group was part of the PACE-A inclusion criteria.
Meanwhile, for RP, guidelines do not recommend adjuvant ADT.
So, the favorable result of SBRT over RP in sexual function only reflects the confines of the study where ADT was not allowed for the enrolled patients and does not reflect the reality that SBRT still lacks sufficient evidence to omit ADT.
